Highlights
- The FDA accepted the lonvo-z Biologics license application with priority review, and the PDUFA goal date is March 10, 2027.
- In the HAELO trial, lonvo-z showed an 87% mean attack-rate reduction from weeks 5 to 28 versus placebo.
- Infusion-related reactions occurred in 51 of 93 patients treated with lonvo-z 50 mg, and two Grade 3 serious events occurred.
- Intellia said payer outreach began in early 2025 and covers more than 280 million U.S. lives for the planned launch.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares were trading at USD 10.14 on November 20, 2026, up 6.51%, with a relative Volume at time of 2.01. The gene editing company hosted a webcast on November 12, 2026 titled "Readying Lonvo-z for Patients with HAE" and furnished its presentation in a Form 8-K.
Intellia Therapeutics, Inc. is a Delaware corporation with principal executive offices in Cambridge, Massachusetts. The company develops investigational in vivo CRISPR-based therapies for severe diseases. Its lead program, lonvoguran ziclumeran, known as lonvo-z and previously NTLA-2002, is being developed as a one-time treatment for hereditary angioedema, or HAE. The company also has Phase 3 trials ongoing in transthyretin amyloidosis, including ATTR-CM and ATTR-PN, with nexiguran ziclumeran.
Regulatory Status of Lonvo-z
The presentation states that the U.S. Food and Drug Administration accepted the biologics license application for lonvo-z for the treatment of HAE and granted priority review. The PDUFA goal date is March 10, 2027. In a communication dated September 3, 2026, the FDA said, "We are not currently planning to hold an advisory committee to discuss this application."
The company said its forward-looking statements include its ability to obtain approval of the application and to launch lonvo-z. The presentation describes lonvo-z as an investigational product not yet approved by regulatory authorities.
Phase 3 HAELO Trial Results
The presentation reports that the Phase 3 HAELO trial achieved its primary and all key secondary endpoints, with a data cutoff of February 10, 2026. The trial included 52 patients in the lonvo-z group and 28 in the placebo group.
For the primary endpoint, the mean attack-rate reduction from weeks 5 to 28 was 87%, with a 95% confidence interval of 78% to 93% and p<0.0001. For the key secondary endpoint of attack-free status in weeks 5 to 28, 62% of lonvo-z patients were attack free, compared with 11% on placebo, with an odds ratio of 12.8 and a 95% confidence interval of 3.5 to 47.6.
Among the 35 of 52 lonvo-z patients taking long-term prophylaxis at study entry, the presentation reports an 81% reduction in attack rate after lonvo-z.
Integrated Safety and Follow-Up
The integrated analysis covers 117 patients across the Phase 1/2 and Phase 3 studies, of whom 93 received one lonvo-z 50 mg dose. The company reported follow-up of up to four years in the earliest patients.
Among the 93 patients who received lonvo-z 50 mg, 82 (88%) reported any treatment-emergent adverse event. Infusion-related reactions were reported in 51 patients (55%), headache in 18 (19%), fatigue in 17 (18%).
Two patients had Grade 3 treatment-emergent adverse events, both classed as serious adverse events: one pulmonary embolism, reported 12 months after infusion in a patient with multiple risk factors, and one perforated appendicitis, reported 22 months after infusion and not considered treatment-related.
Commercial Preparations
The presentation outlines launch preparations for lonvo-z if it is approved. Intellia said it has built payer account, reimbursement, strategic account, field medical, sales and patient services teams.
On payer access, the company said its outreach began in early 2025 and covers more than 280 million U.S. lives. It said it is preparing a network of authorized treatment centers, with a goal that most patients are within 100 miles of a center.
On education, the company said its digital campaign launched in May 2026 and reached 95% of HAE prescribers, and its field engagement began in September 2026 with 1,300 priority healthcare providers who have more than two HAE patients. Upon approval, the company said it plans to begin product promotion through digital and field engagement.






Please wait processing your request...